Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
Debt to Equity
0
ROE
-1.69 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
5.4
CFO
CHF-68.30 Mln
EBITDA
CHF-83.37 Mln
Net Profit
CHF-88.41 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Addex Therapeutics - ADR
| -3.57 | -11.88 | -15.31 | -66.33 | -59.58 | -47.55 | -- |
|
BSE Sensex*
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Addex Therapeutics - ADR
| 15.56 | -51.98 | -89.98 | -53.06 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead... programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Address: Chemin des Mines, 9, Geneva, Switzerland, 1202 Read more
Co-Founder, CEO & Director
Mr. Timothy Mark Dyer
Co-Founder, CEO & Director
Mr. Timothy Mark Dyer
Headquarters
Geneva
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Addex Therapeutics Ltd - ADR stood at $ 13 Mln as on 30-Sep-24
The share price of Addex Therapeutics Ltd - ADR is $6.75 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Addex Therapeutics Ltd - ADR has given a return of -59.58% in the last 3 years.
Addex Therapeutics Ltd - ADR has a market capitalisation of $ 8 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Addex Therapeutics Ltd - ADR is 0.60 times as on 21-Apr-2025, a 74% discount to its peers’ median range of 2.30 times.
Since, TTM earnings of Addex Therapeutics Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Addex Therapeutics Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Addex Therapeutics Ltd - ADR.
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Address: Chemin des Mines, 9, Geneva, Switzerland, 1202
The CEO & director of Mr. Timothy Mark Dyer. is Addex Therapeutics Ltd - ADR, and CFO & Sr. VP is Mr. Timothy Mark Dyer.
There is no promoter pledging in Addex Therapeutics Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Addex Therapeutics Ltd - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-676.44
|
|
Net Margin(%)
|
969.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Addex Therapeutics Ltd - ADR was $0 Mln.
$-0.75
(
